Trial Profile

A Phase Ib/II Clinical Trial of Nous-209 for Recurrent Neoantigen Immunogenicity and Cancer Immune Interception in Lynch Syndrome

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 04 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NOUS-209 (Primary)
Indications Hereditary nonpolyposis colorectal cancer
Focus Adverse reactions; Pharmacodynamics

Most Recent Events

14 Aug 2025 Planned End Date changed from 31 Jul 2025 to 31 Jul 2026.
30 Apr 2025 Results assessing the full set of safety and immunogenicity results of a Phase Ib/II study of Nous-209 monotherapy in Lynch syndrome carriers were presented at the 116th Annual Meeting of the American Association for Cancer Research.
29 Apr 2025 According to Nouscom media release, complete safety and immunogenicity results from this study presented at the American Association for Cancer Research (AACR) Annual Meeting 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com